Precision oncology and systemic targeted therapy in pseudomyxoma peritonei
Authors
Martínez-Quintanilla, J.Cabot, D.
Sabia, D.
Arqués, O.
Vergés, J.
Chicote, I.
Bijelic, L.
Cabellos, L.
Alcántara, A. M.
Ramos, I.
Barrios, P.
Crusellas, O.
Palacio, L. M.
Cámara, J. A.
Barriuso, J.
Jiménez, J. J.
Muñoz-Torres, P.
Nonell, L.
Flores, R.
Médico, E.
Guaglio, M.
Ros, J.
Élez, E.
Tabernero, J.
Aziz, Omer
Deraco, M.
Palmer, H. G.
Affiliation
The Christie NHS Foundation Trust, Manchester, United Kingdom.Issue Date
2024
Metadata
Show full item recordAbstract
PURPOSE: Pseudomyxoma peritonei (PMP) is a rare and poorly understood malignant condition characterized by the accumulation of intra-abdominal mucin produced from peritoneal metastases. Currently, cytoreductive surgery remains the mainstay of treatment but disease recurrence and death after relapse frequently occur in PMP patients. New therapeutic strategies are therefore urgently needed for these patients. EXPERIMENTAL DESIGN: A total of 120 PMP samples from 50 patients were processed to generate a collection of 50 patient-derived organoids (PDO) and xenograft (PDX) models. Whole exome sequencing (WES), immunohistochemistry analyses and in vitro and in vivo drug efficacy studies were performed. RESULTS: In this study, we have generated a collection of PMP preclinical models and identified druggable targets, including BRAFV600E, KRASG12C and KRASG12D,that could also be detected in intra-abdominal mucin biopsies of PMP patients using droplet digital PCR. Preclinical models preserved the histopathological markers from the original patient sample. The BRAFV600E inhibitor encorafenib reduced cell viability of BRAFV600E PMP-PDO models. Proof-of-concept in vivo experiments showed that a systemic treatment with encorafenib significantly reduced tumor growth and prolonged survival in subcutaneous and orthotopic BRAFV600E-PMP-PDX mouse models. CONCLUSIONS: Our study demonstrates for the first time that systemic targeted therapies can effectively control PMP tumors. BRAF signaling pathway inhibition represents a new therapeutic opportunity for BRAFV600E PMP patients who have a poor prognosis. Importantly, our present data and collection of preclinical models pave the way for evaluating the efficacy of other systemic targeted therapies toward extending the promise of precision oncology to PMP patients.Citation
Martínez-Quintanilla J, Cabot D, Sabia D, Arqués O, Vergés J, Chicote I, et al. Precision oncology and systemic targeted therapy in Pseudomyxoma Peritonei. Clinical cancer research : an official journal of the American Association for Cancer Research. 2024 Jul 17. PubMed PMID: 39018564. Epub 2024/07/17. eng.Journal
Clinical Cancer ResearchPubMed ID
39018564Language
enCollections
Related articles
- Appendix-derived Pseudomyxoma Peritonei (PMP): Molecular Profiling Toward Treatment of a Rare Malignancy.
- Authors: Gleeson EM, Feldman R, Mapow BL, Mackovick LT, Ward KM, Morano WF, Rubin RR, Bowne WB
- Issue date: 2018 Aug
- Patient-derived xenograft mouse models of pseudomyxoma peritonei recapitulate the human inflammatory tumor microenvironment.
- Authors: Kuracha MR, Thomas P, Loggie BW, Govindarajan V
- Issue date: 2016 Apr
- Chronic anti-inflammatory drug therapy inhibits gel-forming mucin production in a murine xenograft model of human pseudomyxoma peritonei.
- Authors: Choudry HA, Mavanur A, O'Malley ME, Zeh HJ, Guo Z, Bartlett DL
- Issue date: 2012 May
- Kras mutations and p53 overexpression in pseudomyxoma peritonei: association with phenotype and prognosis.
- Authors: Shetty S, Thomas P, Ramanan B, Sharma P, Govindarajan V, Loggie B
- Issue date: 2013 Mar
- The mutational landscape and prognostic indicators of pseudomyxoma peritonei originating from the ovary.
- Authors: Wang B, Yao J, Ma R, Liu D, Lu Y, Shi G, An L, Xia A, Chen F, Pang S, Zhai X, Liu G, Chen S, Xu M, Song L, Xu H
- Issue date: 2021 Apr 15